You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

013

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Hypercholesterolemia, Familial Hypercholesterolemia Trial (MK-0616, Placebo)

Not yet recruiting
  • Hypercholesterolemia
  • Familial Hypercholesterolemia
  • (no location specified)
Jul 10, 2023

Advanced Hepatocellular Carcinoma (HCC) Trial in Hong Kong (MGD013 monotherapy, MGD013 in combination with Brivanib Alaninate)

Terminated
  • Advanced Hepatocellular Carcinoma (HCC)
  • MGD013 monotherapy
  • MGD013 in combination with Brivanib Alaninate
  • Hong Kong, Hong Kong, China
    Prince of Wales Hospital
Jun 8, 2022

Triple Negative Breast Cancer (TNBC) Trial in China (B013+Nab-Paclitaxel)

Recruiting
  • Triple Negative Breast Cancer (TNBC)
  • Guangzhou, Guangdong, China
  • +6 more
Jan 29, 2023

Hypertension and Dyslipidemia Trial in Seoul (CKD-386(5), D013, D326, D337)

Not yet recruiting
  • Hypertension and Dyslipidemia
  • Seoul, Korea, Republic of
    H plus Yangji hospital
Jan 16, 2023

Hypertension and Dyslipidemia Trial in Seoul (CKD-386(4) F1, CKD-386(4) F2, D013, D326, D337)

Completed
  • Hypertension and Dyslipidemia
  • CKD-386(4) F1
  • +2 more
  • Seoul, Korea, Republic of
    H+ Yangji Hospita
Jan 10, 2023

Ovarian Cancer Trial in Hangzhou (mesothelin-specific chimeric antigen receptor T cell injection)

Recruiting
  • Ovarian Cancer
  • mesothelin-specific chimeric antigen receptor T cell injection
  • Hangzhou, China
    First affiliated hospital, School of Medicine, Zhejiang Universi
May 12, 2022

Melanoma Trial in United States (CAVATAK, Ipilimumab)

Completed
  • Melanoma
  • Duarte, California
  • +10 more
Jan 12, 2023

MDD, Generalized Anxiety Disorder Trial in New York (HPDT-DA-013)

Recruiting
  • Major Depressive Disorder
  • Generalized Anxiety Disorder
  • HPDT-DA-013
  • New York, New York
    Happify Health (Remote)
Aug 5, 2022

Non-alcoholic Fatty Liver Disease, Fatty Liver, Nonalcoholic, NAFLD Trial (Efinopegdutide, Semaglutide, Placebo)

Not yet recruiting
  • Non-alcoholic Fatty Liver Disease
  • +4 more
  • (no location specified)
May 17, 2023

Mobile Applications, Pain, Postoperative, Smartphone Trial in Seoul (A new smart device application (Smart APS))

Recruiting
  • Mobile Applications
  • +3 more
  • A new smart device application (Smart APS)
  • Seoul, Korea, Republic of
    Seoul National University Hospital
Aug 29, 2023

Modified Frailty Index for Minimally Invasive Distal

Completed
  • Postoperative Complication
  • Modified frailty index
  • Seoul, Republic Of Korea, Korea, Republic of
    Asan medical center
Apr 19, 2023

Head Neck Cancer, Squamous Cell Carcinoma of Head and Neck Trial (enoblituzumab, MGA012, MGD013)

Withdrawn
  • Head and Neck Cancer
  • Squamous Cell Carcinoma of Head and Neck
  • enoblituzumab
  • +2 more
  • (no location specified)
Feb 4, 2022

Hyperkalemia Trial in United States (RDX013, Placebo)

Completed
  • Hyperkalemia
  • Coral Gables, Florida
  • +5 more
May 3, 2022

Enhanced Recovery After Surgery Trial in Seoul (ERAS protocol)

Not yet recruiting
  • Enhanced Recovery After Surgery
  • ERAS protocol
  • Seoul, Korea, Republic of
    Seoul National University Hospital
Dec 5, 2022

Pulmonary Hypertension Trial in Lexington (MK-5475, Placebo)

Recruiting
  • Pulmonary Hypertension
  • Lexington, Kentucky
    Lexington VA Medical Center - Cooper Division ( Site 0137)
Jan 8, 2023

Tumors, Colorectal Cancer Trial in Grand Rapids, Nashville, Kirkland (MK-8353, Pembrolizumab)

Completed
  • Neoplasms
  • Colorectal Cancer
  • Grand Rapids, Michigan
  • +2 more
Dec 21, 2022

Acute GVHD in Intestine, Steroid Refractory GVHD Trial in France, Germany, Spain (MaaT013)

Recruiting
  • Acute Graft Versus Host Disease in Intestine
  • Steroid Refractory GVHD
  • Amiens, France
  • +17 more
Jun 20, 2022

Meaning of Recovery After Lung Cancer Surgery

Recruiting
  • Recovery
  • +2 more
    • Seoul, Korea, Republic of
      Seoul National University Hospital
    Jul 22, 2022

    Hypertension and Dyslipidemia Trial (CKD-386(3), D013, D326, D337)

    Not yet recruiting
    • Hypertension and Dyslipidemia
    • (no location specified)
    Feb 16, 2022

    Melanoma Trial in Nantes, Paris, Villejuif (MaaT013, Ipilimumab, Nivolumab)

    Recruiting
    • Melanoma
    • Nantes, France
    • +2 more
    Mar 28, 2022

    Advanced Gastric Cancer Trial in China (fruquintinib +paclitaxel, fruquintinib + paclitaxel)

    Active, not recruiting
    • Advanced Gastric Cancer
    • fruquintinib +paclitaxel
    • fruquintinib placebo + paclitaxel
    • Hefei, Anhui, China
    • +6 more
    Aug 16, 2022

    Unresectable, Recurrent or Metastatic Melanoma, Untreated Mucosal or Acral Lentiginous Melanoma Trial in China (MGD013)

    Terminated
    • Unresectable, Recurrent or Metastatic Melanoma
    • Untreated Mucosal or Acral Lentiginous Melanoma
    • Beijing, Beijing, China
    • +12 more
    Apr 12, 2022

    Advanced Colorectal Carcinoma, Liver Metastasis Colon Cancer Trial in Beijing (Fruquintinib, Hepatic Arterial Infusion

    Recruiting
    • Advanced Colorectal Carcinoma
    • Liver Metastasis Colon Cancer
    • Beijing, Beijing, China
      Beijing Cancer Hospital
    Jun 1, 2022

    Lupus Nephritis Trial in China (efgartigimod IV, Placebo)

    Recruiting
    • Lupus Nephritis
    • efgartigimod IV
    • Placebo
    • Beijing, China
    • +9 more
    Apr 11, 2023

    Postoperative Pain Trial in Seoul (Acetaminophen/Ibuprofen fixed-dose combination)

    Not yet recruiting
    • Postoperative Pain
    • Acetaminophen/Ibuprofen fixed-dose combination
    • Seoul, Korea, Republic of
      Seoul National University Hospital
    Jan 5, 2023